CAREPNEUMO
Combating Antibiotics Resistant Pneumococci by Novel Strategies Based on in vivo and in vitro Host – Pathogen Interactions
| Coordinatore | HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
Organization address
address: Inhoffenstrasse 7 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 3˙969˙999 € |
| EC contributo | 2˙999˙999 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-FP |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-03-01 - 2012-02-29 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
Organization address
address: Inhoffenstrasse 7 contact info |
DE (BRAUNSCHWEIG) | coordinator | 648˙992.00 |
| 2 |
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Organization address
address: CALLE SERRANO 117 contact info |
ES (MADRID) | participant | 344˙115.00 |
| 3 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 277˙992.00 |
| 4 |
Nome Ente NON disponibile
Organization address
address: Domstrasse 11 contact info |
DE (GREIFSWALD) | participant | 256˙800.00 |
| 5 |
UNIVERSITAETSSPITAL BASEL
Organization address
address: HEBELSTRASSE 32 contact info |
CH (BASEL) | participant | 247˙200.00 |
| 6 |
UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE
Organization address
address: AVENIDA DE LA UNIVERSIDAD S/N contact info |
ES (ELCHE) | participant | 222˙000.00 |
| 7 |
UNIVERSITAETSKLINIKUM AACHEN
Organization address
address: Pauwelsstrasse 30 contact info |
DE (AACHEN) | participant | 199˙980.00 |
| 8 |
INSTITUTO DE MEDICINA MOLECULAR
Organization address
address: AVENIDA PROF EGAS MONIZ contact info |
PT (LISBOA) | participant | 155˙100.00 |
| 9 |
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Organization address
address: CHRISTOU LADA 6 contact info |
EL (ATHENS) | participant | 155˙100.00 |
| 10 |
Protea Vaccine Technologies Ltd.
Organization address
address: South Industrial Area contact info |
IL (Kiryat Shmone) | participant | 152˙400.00 |
| 11 |
NARODOWY INSTYTUT LEKOW
Organization address
address: ULICA CHELMSKA 30/34 contact info |
PL (WARSZAWA) | participant | 138˙600.00 |
| 12 |
HOSPITAL DE PEDIATRIA SAMIC PROF. DR. JUAN P. GARRAHAN
Organization address
address: Combate de los Pozos 1881 contact info |
AR (BUENOS AIRES) | participant | 129˙420.00 |
| 13 |
POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH
Organization address
address: "SECTOR 12, POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH" contact info |
IN (CHANDIGARH) | participant | 72˙300.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The diseases caused by Streptococcus pneumoniae are a major public health problem all over the world. Children, elderly people and immuno-compromised individuals are the high-risk targets for pneumococcal diseases. In spite of the availability of a large number of antibiotics the mortality and morbidity due to S. pneumoniae infections remain very high. There are two reasons for this: Firstly, the increasing antibiotic resistance among pneumococcal strains, and secondly, a current vaccine, though effective for certain serotypes, leads to serotype replacement. For the development of combat strategies it is essential to identify new intervention strategies, for which an understanding of host-pathogen interaction is a prerequisite. This proposal would apply a multi-disciplinary approach that includes epidemiology, host-pathogen interactions, infection models and intervention strategies to combat antibiotic resistant S. pneumoniae. The consortium brings together 12 research organizations and 1 SME with expertise in the above-mentioned areas. The major objectives of this consortium will be 1. monitoring of prevalent S. pneumoniae serotypes and their resistance profiles in different countries, 2. analysis of host-pathogen interactions and identification of potential therapeutic targets and vaccine candidates, 3. providing a basis for the development of improved vaccine and intervention strategies. This joint international effort would contribute towards novel control strategies, especially of antibiotic resistant S. pneumoniae strains.'